An Open-label, Single Arm, Phase II Study to Evaluate Efficacy and Safety of Avapritinib BLU-285, A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis

Brief Summary

Type:
Other

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT03580655

Study #:
STUDY00144128

Start Date:
Apr 07, 2020

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03580655

View Complete Trial Details & Eligibility at ClinicalTrials.gov